RU2003131695A - Способ воздействия на нейродегенеративное нарушение или нарушение миелинизации - Google Patents

Способ воздействия на нейродегенеративное нарушение или нарушение миелинизации Download PDF

Info

Publication number
RU2003131695A
RU2003131695A RU2003131695/14A RU2003131695A RU2003131695A RU 2003131695 A RU2003131695 A RU 2003131695A RU 2003131695/14 A RU2003131695/14 A RU 2003131695/14A RU 2003131695 A RU2003131695 A RU 2003131695A RU 2003131695 A RU2003131695 A RU 2003131695A
Authority
RU
Russia
Prior art keywords
disorders
polyneuropathy
disturbance
subject
peripheral
Prior art date
Application number
RU2003131695/14A
Other languages
English (en)
Other versions
RU2266129C2 (ru
Inventor
Джон С. О`БРАЙЕН (US)
Джон С. О`БРАЙЕН
Original Assignee
Риджентс Оф Дзе Юниверсити Оф Калифорния (Us)
Риджентс оф Дзе Юниверсити оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Риджентс Оф Дзе Юниверсити Оф Калифорния (Us), Риджентс оф Дзе Юниверсити оф Калифорния filed Critical Риджентс Оф Дзе Юниверсити Оф Калифорния (Us)
Publication of RU2003131695A publication Critical patent/RU2003131695A/ru
Application granted granted Critical
Publication of RU2266129C2 publication Critical patent/RU2266129C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Claims (6)

1. Способ воздействия на нейродегенеративные нарушения и нарушения миелинизации у субъекта путем введения субъекту нуждающемуся в этом эффективного количества пептида, содержащего аминокислотную последовательность Thr-R1-Lue-Ile-Asp-Asn-Asn-Ala-Thr-Glu-Glu-Ile-Leu-Tyr, где R1 является D-аланином (SEQ ID N:2).
2. Способ по п.1, в котором указанные нарушения выбирают из группы, содержащей: полиневропатию, мононевропатию, неврому, сдавливание нерва, травма нерва, контузия, опухоль или неполное пересечение спинного мозга, инфаркт или травму стволового мозга, таламуса или коры головного мозга, сдавливание, разрыв или воспаление дорсальных корней ганглиев, постполиосиндром, травматическое или ишемическое нарушение центральной или периферической нервной системы, рассеянный склероз.
3. Способ по п.2, в котором полиневропатия представляет собой диабетическую периферийную невропатологию.
4. Способ по п.2, в котором полиневропатия представляет собой периферийную невропатологию, приобретенную в результате хемиотерапии.
5. Способ по п.1, в котором указанными нарушениями являются ишемические нарушения в центральной или переферической нервной системе.
6. Способ по п.1, в котором указанный пептид находится в форме, приемлемой для введения путем, выбранным из группы, включающей: внутривенное, внутримышечное, внутрикожное, подкожное, интракраниальное, в цереброспинальную жидкость, местное, пероральное, чрезкожное трансмукозальное или интраназальное введение.
RU2003131695/14A 1996-03-05 1997-03-05 Способ воздействия на нейродегенеративное нарушение или нарушение миелинизации RU2266129C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/611,307 1996-03-05
US08/611,307 US6271196B1 (en) 1996-03-05 1996-03-05 Methods of alleviating neuropathic pain using prosaposin-derived peptides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU98118091/04A Division RU2223969C2 (ru) 1996-03-05 1997-03-05 Способы облегчения нейропатической боли с применением пептидов, являющихся производными просапозина

Publications (2)

Publication Number Publication Date
RU2003131695A true RU2003131695A (ru) 2005-04-10
RU2266129C2 RU2266129C2 (ru) 2005-12-20

Family

ID=24448513

Family Applications (2)

Application Number Title Priority Date Filing Date
RU98118091/04A RU2223969C2 (ru) 1996-03-05 1997-03-05 Способы облегчения нейропатической боли с применением пептидов, являющихся производными просапозина
RU2003131695/14A RU2266129C2 (ru) 1996-03-05 1997-03-05 Способ воздействия на нейродегенеративное нарушение или нарушение миелинизации

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU98118091/04A RU2223969C2 (ru) 1996-03-05 1997-03-05 Способы облегчения нейропатической боли с применением пептидов, являющихся производными просапозина

Country Status (16)

Country Link
US (2) US6271196B1 (ru)
EP (1) EP0929569B1 (ru)
JP (1) JP4138006B2 (ru)
KR (1) KR100507715B1 (ru)
AT (1) ATE340187T1 (ru)
AU (1) AU734566B2 (ru)
CA (1) CA2248139C (ru)
CZ (1) CZ297384B6 (ru)
DE (1) DE69736712T2 (ru)
IL (1) IL126082A0 (ru)
NO (1) NO984093L (ru)
NZ (1) NZ331757A (ru)
PL (1) PL187917B1 (ru)
RU (2) RU2223969C2 (ru)
SK (1) SK122898A3 (ru)
WO (1) WO1997032895A1 (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) * 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US6849602B1 (en) * 1996-03-05 2005-02-01 The Regents Of The University Of California Compositions for alleviating neuropathic pain with prosaposin receptor agonists
WO1998039357A1 (en) * 1997-03-05 1998-09-11 The Regents Of The University Of California Method of alleviating neuropathic pain
AU4267297A (en) * 1997-09-11 1998-09-22 Regents Of The University Of California, The Method of alleviating neuropathic pain
AU7795698A (en) * 1997-03-24 1998-10-20 Myelos Corporation Synthetic saposin c-derived neurotrophic peptides
EP1011709A4 (en) * 1997-09-09 2003-06-18 Univ California APOPTOSE INHIBITION BY PROSAPOSIN RECEPTORAGONISTS
US6458357B1 (en) * 1997-09-09 2002-10-01 Myelos Corporation Retro-inverso neurotrophic and analgesic peptides
CA2341810A1 (en) * 1998-08-28 2000-03-09 Myelos Corporation Cyclic prosaposin-derived peptides and uses thereof
US20020028783A1 (en) * 1999-09-09 2002-03-07 O'brien John S. Method of stimulating prosaposin receptor activity
USRE45976E1 (en) * 1999-02-24 2016-04-19 Tact Ip, Llc Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally
AU4328500A (en) * 1999-03-30 2000-10-16 Myelos Corporation Retro-inverso prosaposin-derived peptides and use thereof
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
CA2376394A1 (en) * 1999-06-16 2000-12-21 David E. Wright Retro-inverso peptides derived from interleukin-3
WO2000077033A1 (en) * 1999-06-16 2000-12-21 Myelos Corporation Retro-inverso peptides derived from interleukin-6
CA2376474A1 (en) * 1999-06-16 2000-12-21 David E. Wright Retro-inverso peptides derived from leukemia inhibitory factor
US7109168B1 (en) 2000-06-16 2006-09-19 Myelos Corporation Retro-inverso peptides derived from leukemia inhibitory factor
US7135461B1 (en) 2000-06-16 2006-11-14 Myelos Corporation Retro-inverso peptides derived from interleukin-6
US20050074747A1 (en) * 2000-09-08 2005-04-07 Wadih Arap Biopanning and rapid analysis of selective interactive ligands (brasil)
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7420030B2 (en) * 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20060287240A1 (en) * 2001-03-09 2006-12-21 O'brien John S Method of stimulating prosaposin receptor activity
US20040176290A1 (en) * 2001-07-18 2004-09-09 Renata Pasqualini Anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US8507445B2 (en) * 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US20040048243A1 (en) * 2001-09-07 2004-03-11 Wadih Arap Methods and compositions for in vitro targeting
WO2004016167A1 (en) * 2002-08-16 2004-02-26 The General Hospital Corporation Non-invasive functional imaging of peripheral nervous system activation in humans and animals
US7166691B2 (en) * 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
US20060275274A1 (en) * 2003-03-26 2006-12-07 Daria Onichtchouk Use of saposin-related proteins for preventing and treating obesity, diabetes and/or metabolic syndrome
JP2006521399A (ja) * 2003-03-28 2006-09-21 アカディア ファーマシューティカルズ，インコーポレーテッド 疼痛管理用ムスカリンｍ１受容体アゴニスト
US7834147B2 (en) * 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
CN100366286C (zh) * 2003-04-28 2008-02-06 常州南云科技有限公司 Saposin C-DOPS:一种抗癌新药
US9345745B2 (en) * 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US7964585B2 (en) * 2006-03-14 2011-06-21 Case Western Reserve University Composition and method of treating peripheral neuropathy
SG10201604530SA (en) 2008-01-22 2016-07-28 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
RU2561582C2 (ru) * 2010-11-19 2015-08-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Инъекционная лекарственная форма олигопептидного препарата для лечения рассеянного склероза и способ ее получения
JP5971729B2 (ja) * 2011-02-23 2016-08-17 北海道公立大学法人 札幌医科大学 疼痛を治療、改善、または予防するための組成物
RU2669692C1 (ru) * 2017-08-14 2018-10-15 Павел Андреевич Канаев Способ получения комплекса биологически активных пептидов обладающих нейротропной активностью
JP7081865B2 (ja) * 2018-03-23 2022-06-07 ベキシオン ファーマシューティカルズ インコーポレイテッド サポシンｃ薬学的組成物および癌を治療する方法
CN111936508A (zh) 2018-03-29 2020-11-13 横向知识产权私人有限公司 环肽及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0246753B1 (en) 1986-04-22 1994-07-13 The Salk Institute For Biological Studies Fibroblast growth factor antagonists
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
WO1998039357A1 (en) * 1997-03-05 1998-09-11 The Regents Of The University Of California Method of alleviating neuropathic pain
AU7795698A (en) * 1997-03-24 1998-10-20 Myelos Corporation Synthetic saposin c-derived neurotrophic peptides

Also Published As

Publication number Publication date
CZ283998A3 (cs) 1999-05-12
RU2266129C2 (ru) 2005-12-20
DE69736712T2 (de) 2007-09-13
SK122898A3 (en) 2000-02-14
AU734566B2 (en) 2001-06-14
US6268347B1 (en) 2001-07-31
EP0929569B1 (en) 2006-09-20
ATE340187T1 (de) 2006-10-15
EP0929569A4 (en) 2000-08-23
JP4138006B2 (ja) 2008-08-20
US6271196B1 (en) 2001-08-07
EP0929569A1 (en) 1999-07-21
WO1997032895A1 (en) 1997-09-12
KR100507715B1 (ko) 2006-05-26
NZ331757A (en) 1999-10-28
CA2248139C (en) 2004-05-18
AU2328697A (en) 1997-09-22
CZ297384B6 (cs) 2006-11-15
IL126082A0 (en) 1999-05-09
PL187917B1 (pl) 2004-11-30
KR19990087686A (ko) 1999-12-27
PL328701A1 (en) 1999-02-15
DE69736712D1 (de) 2006-11-02
NO984093D0 (no) 1998-09-04
RU2223969C2 (ru) 2004-02-20
CA2248139A1 (en) 1997-09-12
JP2000506853A (ja) 2000-06-06
NO984093L (no) 1998-11-04

Similar Documents

Publication Publication Date Title
RU2003131695A (ru) Способ воздействия на нейродегенеративное нарушение или нарушение миелинизации
Wada et al. Persistent seizure susceptibility and recurrent spontaneous seizures in kindled cats
Oppenheim et al. Reduction of naturally occurring motoneuron death in vivo by a target-derived neurotrophic factor
Fredens et al. The Gordon phenomenon induced by the eosinophil cationic protein and eosinophil protein X
Jaim-Etcheverry et al. DSP-4: a novel compound with neurotoxic effects on noradrenergic neurons of adult and developing rats
El Mahdi et al. The spinal nerve root “innervation”, and a new concept of the clinicopathological inter-relations in back pain and sciatica
EA200100570A1 (ru) Карбоновые кислоты и карбоновокислотные изостеры n-гетероциклических соединений
Saade et al. Supraspinal modulation of nociception in awake rats by stimulation of the dorsal column nuclei
Hernandez-Peon et al. An experimental study of the anticonvulsive and relaxant actions of Valium
Gros et al. Long term results of stereotaxic surgery for infantile dystonia and dyskinesia
Gage et al. Local regulation of compensatory noradrenergic hyperactivity in the partially denervated hippocampus
Marrosu et al. Localized epileptiform activity induced by murine CRF in rats
Bimpong-Buta et al. Carbamazepine-induced choreoathetoid dyskinesias.
Kaji et al. Effect of digitalis on central demyelinative conduction block in vivo
Mearow The effects of NGF and sensory nerve stimulation on collateral sprouting and gene expression in adult sensory neurons
WO1993000427A3 (en) Neurite growth regulatory factors
Puca et al. Topographic analysis of steady-state visual evoked potentials (SVEPs) in the medium frequency range in migraine with and without aura
Kaada et al. Analgesia induced by trigeminal nerve stimulation (electro-acupuncture) abolished by nuclei raphe lesions in rats
Broseta et al. High-frequency cervical spinal cord stimulation in spasticity and motor disorders
Ehle Effects of phenytoin on amygdaloid kindled seizures in the rat
Escandon et al. Developmental expression of the chicken nerve growth factor receptor gene during brain morphogenesis
Czuczwar et al. Effects of some antiepileptic drugs in pentetrazol‐induced convulsions in mice lesioned with kainic acid
Grahnstedt et al. Awakening thresholds for electrical brain stimulation in five sleep-waking stages in the cat
Fox et al. Changes in F wave size during dentatotomy.
Shieff et al. Stereotactic mesencephalic tractotomy for thalamic pain

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20080306